
Trump's Labor Department proposes more than 60 rule changes in a push to deregulate workplaces
If approved, the wide-ranging changes unveiled this month also would affect working conditions at constructions sites and in mines , and limit the government's ability to penalize employers if workers are injured or killed while engaging in inherently risky activities such as movie stunts or animal training.
The Labor Department says the goal is to reduce costly, burdensome rules imposed under previous administrations, and to deliver on President Donald Trump's commitment to restore American prosperity through deregulation.
'The Department of Labor is proud to lead the way by eliminating unnecessary regulations that stifle growth and limit opportunity,' Secretary of Labor Lori Chavez-DeRemer said in a statement, which boasted the 'most ambitious proposal to slash red tape of any department across the federal government.'
Critics say the proposals would put workers at greater risk of harm , with women and members of minority groups bearing a disproportionate impact.
'People are at very great risk of dying on the job already,' Rebecca Reindel, the AFL-CIO union's occupational safety and health director, said. 'This is something that is only going to make the problem worse.'
The proposed changes have several stages to get through before they can take effect, including a public comment period for each one.
Here's a look at some of the rollbacks under consideration:
Home health care workers help elderly or medically fragile people by preparing meals, administering medications, assisting with toilet use, accompanying clients to doctor appointments and performing other tasks. Under one of the Labor Department's proposals, an estimated 3.7 million workers employed by home care agencies could be paid below the federal minimum wage — currently $7.25 per hour — and made ineligible for overtime pay if they aren't covered by corresponding state laws .
The proposed rule would reverse changes made in 2013 under former President Barack Obama and revert to a regulatory framework from 1975. The Labor Department says that by lowering labor and compliance costs, its revisions might expand the home care market and help keep frail individuals in their homes for longer.
Judy Conti, director of government affairs at the National Employment Law Project, said her organization plans to work hard to defeat the proposal. Home health workers are subject to injuries from lifting clients, and 'before those (2013) regulations, it was very common for home care workers to work 50, 60 and maybe even more hours a week, without getting any overtime pay,' Conti said.
Others endorse the proposal, including the Independent Women's Forum, a conservative nonprofit based in Virginia. Women often bear the brunt of family caregiving responsibilities , so making home care more affordable would help women balance work and personal responsibilities, the group's president, Carrie Lukas, said.
'We're pleased to see the Trump administration moving forward on rolling back some of what we saw as counterproductive micromanaging of relationships that were making it hard for people to get the care they need,' Lukas said.
Samantha Sanders, director of government affairs and advocacy at the nonprofit Economic Policy Institute, said the repeal would not constitute a win for women.
'Saying we actually don't think they need those protections would be pretty devastating to a workforce that performs really essential work and is very heavily dominated by women, and women of color in particular,' Sanders said.
Last year, the Labor Department finalized rules that provided protections to migrant farmworkers who held H-2A visas . The current administration says most of those rules placed unnecessary and costly requirements on employers.
Under the new proposal, the Labor Department would rescind a requirement for most employer-provided transportation to have seat belts for those agriculture workers.
The department is also proposing to reverse a 2024 rule that protected migrant farmworkers from retaliation for activities such as filing a complaint, testifying or participating in an investigation, hearing or proceeding.
'There's a long history of retaliation against workers who speak up against abuses in farm work. And with H-2A it's even worse because the employer can just not renew your visa,' said Lori Johnson, senior attorney at Farmworker Justice.
Michael Marsh, president and CEO of the National Council of Agricultural Employers, applauded the deregulation efforts, saying farmers were hit with thousands of pages of regulations pertaining to migrant farmworkers in recent years.
'Can you imagine a farmer and his or her spouse trying to navigate 3,000 new pages of regulation in 18 months and then be liable for every one of them?' he asked.
The Occupational Safety and Health Administration , part of the Labor Department, wants to rescind a requirement for employers to provide adequate lighting at construction sites, saying the regulation doesn't substantially reduce a significant risk.
OSHA said if employers fail to correct lighting deficiencies at construction worksites, the agency can issue citations under its 'general duty clause.' The clause requires employers to provide a place of employment free from recognized hazards which are likely to cause death or serious physical harm.
Worker advocates think getting rid of a specific construction site requirement is a bad idea. 'There have been many fatalities where workers fall through a hole in the floor, where there's not adequate lighting,' Reindel said. 'It's a very obvious thing that employers should address, but unfortunately it's one of those things where we need a standard, and it's violated all the time.'
Several proposals could impact safety procedures for mines. For example, employers have to submit plans for ventilation and preventing roof collapses in coal mines for review by the Labor Department's Mine Safety and Health Administration . Currently, MSHA district managers can require mine operators to take additional steps to improve those plans.
The Labor Department wants to end that authority, saying the current regulations give the district manager the ability to draft and create laws without soliciting comments or action by Congress.
Similarly, the department is proposing to strip district managers of their ability to require changes to mine health and safety training programs.
The general duty clause allows OSHA to punish employers for unsafe working conditions when there's no specific standard in place to cover a situation.
An OSHA proposal would exclude the agency from applying the clause to prohibit, restrict or penalize employers for 'inherently risky professional activities that are intrinsic to professional, athletic, or entertainment occupations.'
A preliminary analysis identified athletes, actors, dancers, musicians, other entertainers and journalists as among the types of workers the limitation would apply to.
'It is simply not plausible to assert that Congress, when passing the Occupational Safety and Health Act, silently intended to authorize the Department of Labor to eliminate familiar sports and entertainment practices, such as punt returns in the NFL, speeding in NASCAR, or the whale show at SeaWorld ,' the proposed rule reads.
Debbie Berkowitz, who served as OSHA chief of staff during the Obama administration, said she thinks limiting the agency's enforcement authority would be a mistake.
'Once you start taking that threat away, you could return to where they'll throw safety to the wind, because there are other production pressures they have,' Berkowitz said.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
2 minutes ago
- Yahoo
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
32 minutes ago
- Yahoo
Exclusive-China's Sciwind is in talks to license weight-loss drug in US, CEO says
By Andrew Silver HANGZHOU (Reuters) -China's Sciwind Biosciences is in talks with a U.S. company interested in licensing its experimental weight-loss drug for American patients, the drugmaker's chief executive told Reuters. Overweight patients treated with Sciwind's ecnoglutide drug lost an average of 10% to 15% of their body weight, roughly in line with results from Novo Nordisk's top-selling obesity treatment Wegovy, according to a late-stage study published in medical journal The Lancet Diabetes & Endocrinology in June. 'We also hope we are able to successfully license out, and they will apply for approval in the U.S.,' Sciwind Biosciences CEO Pan Hai said, declining to identify the firm or disclose financial terms under discussion. Reuters is the first to report on the potential U.S. licensing deal. Pan said its potential partner hoped to gain U.S. marketing approval to prescribe ecnoglutide for multiple medical conditions and would carry out further clinical development. The talks are not yet at the stage of discussing a detailed contract, he added. Sciwind is hoping the partner could use clinical data accumulated in China and Australia to accelerate the development. Pan expects it would take at least three years for a U.S. partner to bring Sciwind's drug to market in the United States, and said the FDA might require a bridging study to compare ecnoglutide's pharmacokinetics - how it moves through the body - among different patient populations. Ecnoglutide is administered as a once-weekly injection. It belongs to a class of drugs called GLP-1 receptor agonists, which work by helping control blood sugar levels and triggering a feeling of fullness. Novo's Wegovy and Eli Lilly and Co's Zepbound lead the U.S. market for weight-loss drugs, but their relatively high prices leave room for new competitors to offer cheaper alternatives. Sciwind has applied to sell ecnoglutide in China for weight management and the treatment of type II diabetes. Other approved weight loss medicines in China also include drugs from Novo, Lilly and other drugmakers. Pan said he could not give an estimated time of approval. The company is also in talks to license the drug to partners for other markets, including in Latin America and the Middle East. Pricing in China would be in line with other approved competitors, Pan said, adding the company would not engage in a "price war" there. Solve the daily Crossword


Boston Globe
33 minutes ago
- Boston Globe
Europeans and Iran meet in Istanbul as the return of sanctions looms over nuclear deadlock
The return of sanctions, known as a 'snapback' mechanism, 'remains on the table,' according to a European diplomat speaking on condition of anonymity due to the sensitivity of the talks. 'A possible delay in triggering snapback has been floated to the Iranians on the condition that there is credible diplomatic engagement by Iran, that they resume full cooperation with the IAEA (International Atomic Energy Agency), and that they address concerns about their highly-enriched uranium stockpile,' the diplomat said. European leaders have said sanctions will resume by the end of August if there is no progress on containing Iran's nuclear program. Advertisement Tehran, meanwhile, has said the U.S., which withdrew from the 2015 deal during President Donald Trump 's first term, needs to rebuild faith in its role in negotiations. Deputy Foreign Minister Kazem Gharibabadi said Iran's engagement was dependent on 'several key principles' that included 'rebuilding Iran's trust – as Iran has absolutely no trust in the United States.' In a social media post Thursday, he also said the talks shouldn't be used 'as a platform for hidden agendas such as military action.' Gharibabadi insisted that Iran's right to enrich uranium 'in line with its legitimate needs' be respected and sanctions removed. Advertisement Iran has repeatedly threatened to leave the Nuclear Nonproliferation Treaty, which commits it to refrain from developing nuclear weapons, if sanctions return. Friday's talks were being held at the deputy ministerial level, with Iran sending Deputy Foreign Minister Majid Takht-e Ravanchi. A similar meeting was held in Istanbul in May. The identity of the E3 representatives were not immediately clear but the European Union's deputy foreign policy commissioner was thought to be attending. The U.K., France and Germany were signatories to the 2015 deal, alongside the U.S., Russia and China. When the U.S. withdrew in 2018, Trump insisted the agreement wasn't tough enough. Under the original deal, neither Russia nor China can veto reimposed sanctions. Since the Israeli and U.S. strikes on Iran, which saw American B-52 bombers hit three nuclear sites, Iran's Foreign Minister Abbas Araghchi has accused the E3 of hypocrisy, saying they failed to uphold their obligations while supporting Israel's attacks. Against the backdrop of the conflict, which saw Iran respond with missile attacks on Israel and a strike on a U.S. base in Qatar, the road ahead remains uncertain. While European officials have said they want to avoid further conflict and are open to a negotiated solution, they have warned that time is running out. Tehran maintains it is open to diplomacy, though it recently suspended cooperation with the IAEA. A central concern for Western powers was highlighted when the IAEA reported in May that Iran's stockpile of uranium enriched to 60% – just below weapons-grade level – had grown to over 400 kilograms (882 pounds). Advertisement In an interview with Al Jazeera that aired Wednesday, Iranian President Masoud Pezeshkian said Iran is prepared for another war and reiterated that its nuclear program will continue within the framework of international law while adding the country had no intention of pursuing nuclear weapons. A spokesman for Iran's Atomic Energy Organization said Thursday the country's nuclear industry would 'grow back and thrive again' after the recent attacks by Israel and the U.S. Vahdat reported from Tehran, Iran. Associated Press writer Stephanie Lichtenstein in Vienna contributed to this report.